Lyme Disease - Pipeline Review, H2 2012

Global Markets Direct, November 2012, Pages: 34

Lyme Disease – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lyme Disease - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lyme Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lyme Disease. Lyme Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lyme Disease.
- A review of the Lyme Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lyme Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lyme Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lyme Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Lyme Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lyme Disease 7
Lyme Disease Therapeutics under Development by Companies 9
Lyme Disease Therapeutics under Investigation by Universities/Institutes 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Lyme Disease Therapeutics – Products under Development by Companies 13
Lyme Disease Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Lyme Disease Therapeutics Development 15
Baxter International Inc. 15
Zosano Pharma, Inc. 16
Intercell AG 17
Viral Genetics, Inc. 18
Lyme Disease – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Lyme Borreliosis Vaccine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Isac - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Multivalent recombinant OspA Lyme Borreliosis Vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
VGV-L - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Lyme Disease Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Lyme Disease Therapeutics – Drug Profile Updates 29
Lyme Disease Therapeutics - Dormant Products 30
Lyme Disease – Product Development Milestones 31
Featured News & Press Releases 31
Mar 07, 2012: Viral Genetics Submits Pre-IND Document For Lyme Disease Drug Candidate To FDA 31
Oct 21, 2008: Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study and Team Receives Positive Feedback at ILADS Conference, Study Model Potentially Applies to HIV/AIDS and Other Immune Based Diseases. 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34

List of Tables
Number of Products Under Development for Lyme Disease, H2 2012 7
Products under Development for Lyme Disease – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Baxter International Inc., H2 2012 15
Zosano Pharma, Inc., H2 2012 16
Intercell AG, H2 2012 17
Viral Genetics, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Lyme Disease Therapeutics – Drug Profile Updates 29
Lyme Disease Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Lyme Disease, H2 2012 7
Products under Development for Lyme Disease – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012